Clinical trials: Visceral Leishmaniasis
Visceral Leishmaniasis
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
- Trial name
- NCT01122771
- Testing
- Liposomal amphotericin B, liposomal amphotericin B + miltefosine, liposomal amphotericin B + paromomycin
- Where
- 4 sites in Bangladesh
- Volunteers
- 602 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
This modular Program will first confirm the safety and efficacy of Paromomycin IM Injection when given to an expanded population in the outpatient setting in experienced VL centers and subsequently evaluate the effectiveness of…
- Trial name
- NCT00604955
- Testing
- Paromomycin sulfate
- Where
- 7 sites in India
- Volunteers
- 2,000 people
- Sponsor
- PATH
Visceral Leishmaniasis
A Community Trial for Visceral Leishmaniasis (VL)
Visceral leishmaniasis (VL) / Kala-azar (KA) is a public health problem in the many countries in the world including Bangladesh. Where more than 90,000 VL cases have been reported since 1994. The disease is fatal if not treated.
- Trial name
- NCT01069198
- Testing
- Albendazole, Iron, Zinc and Vitamin A
- Where
- 2 sites in Bangladesh
- Volunteers
- 200 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Post-kala-azar Dermal Leishmaniasis
Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh
The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions of 3 mg/kg on an outpatient basis, is evaluated in clinically diagnosed PKDL patients of 12 years and older in a highly endemic area in…
- Trial name
- NCT03311607
- Testing
- AmBisome
- Volunteers
- 280 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Visceral Leishmaniasis
Asymptomatic Leishmania Infection in HIV Patients
To collect pilot data on the prevalence and incidence of asymptomatic Leishmania donovani infection in HIV infected individuals in a visceral leishmaniasis (VL)-HIV endemic region to inform the feasibility of a larger study…
- Trial name
- NCT02839603
- Where
- Ethiopia
- Volunteers
- 540 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan
This study is designed to determine the efficacy of Fexinidazole as an oral treatment in Visceral Leishmanisasis sudanese adults patients.
- Trial name
- NCT01980199
- Testing
- Fexinidazole
- Where
- Sudan
- Volunteers
- 14 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis
LAMP Assay for the Diagnosis of Visceral Leishmaniasis
This study will evaluate the of the loop-mediated amplification assay (LAMP) as a diagnostic as well as a Test-of-Cure (ToC) for visceral leishmaniasis (VL) in an endemic area in Ethiopia.
- Trial name
- EvaLAMP (NCT04003532)
- Where
- Ethiopia
- Volunteers
- 500 people
- Sponsor
- Prof. Dawit Wolday